AIM Vaccine (HKG:6660) said the results of the phase 3 clinical trial of its iterative serum-free rabies vaccine showed the product has good immunogenicity and safety
Compared with other rabies vaccines, the company's vaccine does not contain animal serum and therefore has a reduced probability of causing any adverse reaction making it a safer option globally, the disclosure said.
The top Chinese full-chain vaccine corporation's shares surged nearly 15% in recent trade.
Price (HKD): $12.40, Change: $+1.6, Percent Change: +14.81%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.